Neurocrine Biosciences Inc (NBIX)vsUnited Therapeutics Corporation (UTHR)
NBIX
Neurocrine Biosciences Inc
$163.41
+2.25%
HEALTHCARE · Cap: $16.77B
UTHR
United Therapeutics Corporation
$538.84
+1.11%
HEALTHCARE · Cap: $25.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Neurocrine Biosciences Inc generates 6% more annual revenue ($3.37B vs $3.17B). UTHR leads profitability with a 40.6% profit margin vs 20.9%. NBIX appears more attractively valued with a PEG of 0.47. NBIX earns a higher WallStSmart Score of 81/100 (A-).
NBIX
Exceptional Buy81
out of 100
Grade: A-
UTHR
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NBIX.
Margin of Safety
-14.6%
Fair Value
$415.36
Current Price
$538.84
$123.48 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Revenue surging 39.5% year-over-year
Safe zone — low bankruptcy risk
Keeps 21 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 22.7%
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Revenue Growth, Altman Z-Score. Profitability is solid with margins at 20.9% and operating margin at 22.7%. Revenue growth of 39.5% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : NBIX
The primary concerns for NBIX are Piotroski F-Score.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
NBIX profiles as a growth stock while UTHR is a declining play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.58 — expect wider price swings.
NBIX is growing revenue faster at 39.5% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
NBIX scores higher overall (81/100 vs 55/100), backed by strong 20.9% margins and 39.5% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?